Hyderabad, India (Press Release) – Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has launched a generic version of poma­lido­mide 1 mg, 2 mg, and 4 mg capsules in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name POMALYST®.

Pomalidomide is a thalido­mide analogue indicated, in com­bi­na­tion with dexa­meth­a­sone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior ther­a­pies in­clud­ing lena­lido­mide and a pro­te­a­some inhibitor and have dem­onstrated disease pro­gres­sion on or within 60 days of completion of the last ther­apy.

Natco will mar­ket generic poma­lido­mide capsules under its brand name POMALID in India. Natco priced its generic med­i­cine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP of INR 5000/-, INR 10,000/-, and INR 20,000/- re­spec­tive­ly for a monthly pack of 21 capsules. We believe, this is approx­i­mately 98% discount of price from what it is sold at in the USA to patients, per sec­ond­ary mar­ket data researched.

Source: NATCO.